Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01705067
NCT01705067CompletedNot Applicable

A Retro-Prospective, Non-randomized, Consecutive Series, SIngle Cohort, Multicenter Adaptive Design Study to Evaluate the Outcomes of Total Knee Arthroplasty (TKA) Using JOURNEY™ II BCS TotaL Knee SystEm (The NIMBLE Study)

Smith & Nephew, Inc.12 sites in 1 country209 target enrollmentStarted: June 2012Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
209
Locations
12
Primary Endpoint
Rate of ITB Friction Pain
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Assess the safety and efficacy of the JOURNEY II BCS Total Knee System in subjects with degenerative knee disease requiring primary total knee replacement.

Detailed Description

Assess the safety and efficacy of the JOURNEY II BCS Total Knee System in subjects with degenerative knee disease requiring primary total knee replacement. Pre-operative and operative assessments collected retrospectively. All postoperative assessments beginning at the 6 month post-operative time point collected prospectively.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Other

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Subject received primary total knee arthroplasty with the JOURNEY™ II BCS Total Knee System due to degenerative joint disease
  • •Subject is willing to sign and date an IRB approved consent form
  • •Subject is of legal age to consent
  • •Subject plans to be available through ten (10) years postoperative follow-up
  • •Subject agrees to follow the study protocol

Exclusion Criteria

  • •Subject received the JOURNEY™ II BCS Total Knee System on the affected knee as a revision for a previously failed total or unicondylar knee arthroplasty
  • •Subject received TKA on the contralateral knee as a revision for a previously failed total or unicondylar knee arthroplasty
  • •Subject possesses a contralateral or ipsilateral revision hip arthroplasty
  • •Subject has ipsilateral hip arthritis resulting in flexion contracture
  • •At the time of enrollment, subject has one or more of the following arthroplasties that are not fully healed and well-functioning, as determined by the investigator:
  • •Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty
  • •Contralateral primary total knee or unicondylar knee arthroplasty
  • •At the time of surgery, subject had an active infection or sepsis (treated or untreated)
  • •At the time of surgery, subject had presence of malignant tumor, metastatic, or neoplastic disease
  • •At the time of surgery, subject had conditions that may interfere with the TKA survival or outcome (i.e., Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease)
  • •At the time of surgery, subject had contralateral lower extremity condition causing abnormal ambulation
  • •Subject is pregnant or plans to become pregnant during the study
  • •Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study
  • •At the time of surgery, subject had a BMI>40
  • •At the time of enrollment, subject has a BMI>40
  • •Subject is enrolled in another investigational drug, biologic, or device study
  • •Subject is facing current or impending incarceration

Outcomes

Primary Outcomes

Rate of ITB Friction Pain

Time Frame: 6 months post-operatively

Secondary Outcomes

  • Radiographic Evaluation(Baseline and 6 months post-operatively, 1 year post-operatively, 2 years post-operatively, 5 years post-operatively, and 10 years post-operatively)
  • Adverse Events(6 months post-operatively, 1 year post-operatively, 2 years post-operatively, 5 years post-operatively, and 10 years post-operatively)
  • Knee Society Score(6 months post-operatively, 1 year post-operatively, 2 years post-operatively, 5 years post-operatively, and 10 years post-operatively)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (12)

Loading locations...

Similar Trials

Completed
Not Applicable
Safety and Performance of Journey II BCS Total Knee System Patient Reported Outcome MeasuresJourney II BCS Total Knee System
NCT03903731Smith & Nephew, Inc.600
Withdrawn
Not Applicable
Evaluate the Performance of JOURNEY II CR and JOURNEY II BCS in TKA PopulationsArthroplastyReplacementKnee
NCT04822259Smith & Nephew, Inc.
Active, not recruiting
Not Applicable
Journey II BCS EU Observational TrialDegenerative Joint Disease
NCT02211794Smith & Nephew Orthopaedics AG175
Active, not recruiting
Not Applicable
JOURNEY II XR Safety and Effectiveness PMCFRheumatoid Vasculitis With Rheumatoid Arthritis of KneeUnilateral Post-Traumatic Osteoarthritis of KneeDegenerative Arthritis Peripheral JointKnee OsteoarthritisFailed OsteotomiesFailed Unicompartmental Replacement
NCT03136887Smith & Nephew, Inc.176
Completed
Not Applicable
A Prospective, Multicenter, Study to Evaluate the Safety and Effectiveness of the JOURNEY II XR Total Knee System with VERILAST TechnologyThe subject components are indicated for total knee arthroplasty performed for rheumatoid arthritis, post-traumatic arthritis, osteoarthritis, degenerative arthritis, failed osteotomies, or failed unicompartmental replacement.
JPRN-UMIN000034044Smith & Nephew KK106
Safety and Efficacy of the Journey II BCS... | Clinical Trial